UNSPSC 51331501: Armodafinil or modafinil

This classification denotes a cns stimulant with the molecular formula C15H15NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V63XWA605I, chemically known as acetamide, 2-((diphenylmethyl)sulfinyl)- but generally known as armodafinil, which bears US NIH Compound Identifier 4236. European Medicines Agency schedules Armodafinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32249.

The term ARMODAFINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). Armodafinil or modafinil bears US NLM identifiers UMLS ID C0066677 and NCI Concept Code C26661. SMILES: S(=O)(C(C1CCCCC1)C1CCCCC1)CC(=O)N.

UNSPSC 51331501 Armodafinil or modafinil is a Commodity code that does not align with the state and local procurement activity recently tagged under it. The three most recent opportunities posted under this code involve naloxone and drug-deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy initiatives (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations concern armodafinil or modafinil specifically, indicating a significant mismatch between the code's nominal scope and the work actually being procured. The issuing bodies span county government, state health agencies, and cooperative purchasing consortia, but they are pursuing pharmaceutical sourcing arrangements that fall outside the stated commodity classification.

Geographic activity appears concentrated in Florida, Texas, and Minnesota based on recent postings. The Minnesota MMCAP procurement represents a multistate cooperative vehicle serving state and local government facilities across participating jurisdictions including Oregon, while Seminole County's naloxone procurement serves local community health initiatives in the Central Florida region, and the Texas HHS Commission RFI targets state-level pharmacy benefit reform. The code shows no recent activity aligned with its stated scope of armodafinil or modafinil procurement; business development professionals should verify procurement intent and code classification with issuing bodies before investing pursuit resources, as the current tagging appears to reflect system classification error rather than genuine demand for the specified medication.